CRSP - CRISPR Therapeutics

-

$undefined

N/A

(N/A)

CRISPR Therapeutics NasdaqGM:CRSP CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Location: Baarerstrasse 14, Zug, 6300, Switzerland | Website: https://www.crisprtx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.541B

Cash

1.855B

Avg Qtr Burn

-76.62M

Short % of Float

24.51%

Insider Ownership

1.75%

Institutional Own.

76.60%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

CTX110 (CD19) Details
CD19+ malignancies, B-cell malignancies, Cancer, Blood cancer

Phase 2

Update

Phase 1/2

Update

Phase 1/2

Update

Phase 1/2

Update

CTX130 (CD70) Details
Blood cancer, Cancer, T-cell lymphoma

Phase 1

Update

VCTX210 Details
Type 1 diabetes

Phase 1

Update

CTX131 (CD70) Details
Cancer, Solid tumor/s

Phase 1

Update

CTX112 Details
Systemic lupus erythematosus

Phase 1

Update

CTX112 Details
CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies

Phase 1

Update

CTX310 (ANGPTL3) Details
Atherosclerotic cardiovascular disease

Phase 1

Update

CTX320 Lp(a) Details
Atherosclerotic cardiovascular disease

Phase 1

Update

CTX120 (BCMA) Details
Multiple myeloma, Blood cancer, Cancer

Failed

Discontinued